Clinical Research

Strategy To Combat Genetic Risk Factor For ALS

Amyotrophic lateral sclerosis (Lou Gehrig's disease) is in the popular media because celebrities are dumping buckets of ice on their heads to raise awareness. Researchers probably wish they would donate money to research rather than raising awareness ...

Article - News Staff - Aug 14 2014 - 3:17pm

Experimental Heart Attack Drug APT102 Reduces Tissue Damage

An investigational drug known as APT102 significantly reduced damage to heart muscle from a heart attack and minimized the risk of bleeding during follow-up treatments, according to an animal study based on a decade of work by APT Therapeutics, scientists ...

Article - News Staff - Aug 16 2014 - 7:00am

Rare Stiff Person Syndrome Cured? Two Case Reports

...

Article - News Staff - Aug 25 2014 - 6:30pm

Oxidized Lipids: Protein In HDL May Be Key To Treating Pulmonary Hypertension

Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis. A new study at UCLA demonstrates that they may also contribute to pulmonary hypertension, a serious lung disease th ...

Article - News Staff - Aug 28 2014 - 3:00pm

Sickle Cell Is Still A Killer But This 50 Cent Test Could Change That

A simple solution to a persistent problem. Credit: Ashok A. Kumar By Ashok A. Kumar, Harvard University Every year, 300,000 children are born with sickle-cell disease, primarily in Africa and India. It is a genetic disorder that causes some blood cells to ...

Article - The Conversation - Sep 2 2014 - 12:09pm

MITOCARE: TRO40303 Hopes Dashed For Preventing Reperfusion Injury After Heart Attack

 Reperfusion injury prevention isn't possible just yet. The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusio ...

Article - News Staff - Sep 2 2014 - 10:44am

New Antifungal Isavuconazole As Effective As Voriconazole With Fewer Adverse Events

A newly developed antifungal named isavuconazole is as effective as voriconazole against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data. ...

Article - News Staff - Sep 7 2014 - 8:00pm

Randomized Phase II Clinical Trial Of Pracinostat Set For Front Line Myelodysplastic Syndrome

Enrollment in a randomized Phase II clinical trial of Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS) has been completed. The multi-center, placebo-controlled, dou ...

Article - News Staff - Sep 8 2014 - 8:01am

Fast Track Designation For Motolimod Immunotherapy In Ovarian Cancer

In 2014, there will be an estimated 22,240 new cases of ovarian cancer in the United States and over 40,000 new cases in the European Union. Ovarian cancer is one of the most lethal gynecologic cancers. Women with recurrent or persistent ovarian cancer rec ...

Article - News Staff - Sep 8 2014 - 10:30am

Clinical Trials Of SYN-004 In For C. Difficile Infections Upcoming

Positive results from its final preclinical toxicology study of SYN-004 have led Synthetic Biologics to get ready for clinical trials of the anti-infective, second-generation product candidate for Clostridium difficile (C. difficile). Synthetic Biologics i ...

Article - News Staff - Sep 9 2014 - 8:00am